School of Social Professions, London Metropolitan University, 166-220 Holloway Road, London, N7 8DB, UK.
Int J Equity Health. 2019 Feb 18;18(1):35. doi: 10.1186/s12939-019-0936-z.
Hormonal therapy is an integral component for breast cancer treatment in women with oestrogen receptor positive tumours in early-stage and advanced cases of the disease. Little is known about what factors influence oncologists' prescribing practices, especially non-biological factors, although this information may have important implications for understanding inequalities in health care quality and outcomes. This paper presents findings from research on factors influencing oncologists' prescribing hormonal therapy for women with early and advanced cases of breast cancer in the city of Córdoba, Argentina.
A qualitative study using in-depth, semi-structured interviews with 16 oncologists was conducted. A stratified purposive sampling was used to recruit female and male participants and working at 3 health subsystems (private, social security, public). Data was analysed using the Framework approach.
According to the respondents, factors influencing prescribing practices of hormonal therapy are varied. Women's socio-economic status (poverty and wealth) and their level of health literacy can affect oncologists' prescribing practices. Overall, in comparison to male, female oncologists reported more awareness of patients' needs, more involvement in communicating drug side-effects, and in offering treatment options in private health settings. The 3 health subsystems provided a differential access to drugs and lines of hormonal treatment, which ranged from a limited availability in the public sector, to administrative restrictions imposed by the social security system, and to a lesser extent, the private sector. This happened in the backdrop of national legislation covering oncological treatments and drugs free of charge.
Addressing prescribing practices for hormonal therapy as a distinct type of breast cancer treatment (chronic care) is fundamental in the understanding of breast cancer care and can shed light on inequalities in treatments. Identifying the underlying care gaps in the prescription of hormonal therapy can help in the design of tailored interventions.
在患有雌激素受体阳性肿瘤的早期和晚期乳腺癌女性中,激素治疗是治疗的一个组成部分。尽管这些信息对于了解医疗保健质量和结果的不平等可能具有重要意义,但对于影响肿瘤学家处方实践的因素,特别是非生物学因素,知之甚少。本文介绍了在阿根廷科尔多瓦市对影响肿瘤学家为患有早期和晚期乳腺癌的女性开具激素治疗处方的因素进行研究的结果。
采用深入的半结构式访谈方法,对 16 名肿瘤学家进行了定性研究。采用分层目的抽样法招募女性和男性参与者,并在 3 个卫生子系统(私人、社会保险、公共)工作。使用框架方法分析数据。
根据受访者的说法,影响激素治疗处方实践的因素多种多样。女性的社会经济地位(贫困和富裕)和她们的健康素养水平会影响肿瘤学家的处方实践。总体而言,与男性相比,女性肿瘤学家报告说更了解患者的需求,更参与沟通药物副作用,并在私人卫生环境中提供治疗选择。3 个卫生子系统提供了不同的药物和激素治疗方案的获取途径,从公共部门的供应有限,到社会保险系统施加的行政限制,再到私人部门的限制程度较低。这是在涵盖肿瘤治疗和免费药物的国家立法的背景下发生的。
将激素治疗的处方实践作为一种独特的乳腺癌治疗方法(慢性护理)来处理,对于理解乳腺癌护理至关重要,并可以揭示治疗中的不平等现象。确定激素治疗处方方面的潜在护理差距有助于设计量身定制的干预措施。